CD49d expression as a promising biomarker to monitor natalizumab efficacy
- 1 March 2012
- journal article
- Published by Elsevier BV in Journal of the Neurological Sciences
- Vol. 314 (1-2), 138-142
- https://doi.org/10.1016/j.jns.2011.10.005
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisJournal of the Neurological Sciences, 2010
- GIANT URTICARIA AND PERSISTENT NEUTRALIZING ANTIBODIES AFTER THE FIRST NATALIZUMAB INFUSIONNeurology, 2010
- The implications of immunogenicity for protein-based multiple sclerosis therapiesJournal of the Neurological Sciences, 2008
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Natalizumab effects on immune cell responses in multiple sclerosisAnnals of Neurology, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- A monoclonal antibody to α4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the Guinea pigJournal of Magnetic Resonance Imaging, 1995
- The adhesion molecule and cytokine profile of multiple sclerosis lesionsAnnals of Neurology, 1995
- Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrinNature, 1992